5.06 USD
▼-0.07-1.36%
盘后 5.02 -0.79%
2026-09-15
市值
$999.13M
市盈率
6.40
EPS
0.79
股息率
—
52 周区间
3.50 – 5.45
成交量
4.25M
Beta
0.62
目标价
5.18
52W 低 3.5052W 高 5.45
价格走势
公司简介
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inh...